Pfizer News and Research RSS Feed - Pfizer News and Research

Global Peptic Ulcer Drugs market expected to grow at CAGR of 2.9% over 2013-2018

Global Peptic Ulcer Drugs market expected to grow at CAGR of 2.9% over 2013-2018

Research and Markets has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" report to their offering. [More]
InnoPharma receives FDA approval for generic DACOGEN

InnoPharma receives FDA approval for generic DACOGEN

InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN. [More]
Report: Global Multiple Sclerosis Drugs market to grow at 5.56% CAGR over 2013-2018

Report: Global Multiple Sclerosis Drugs market to grow at 5.56% CAGR over 2013-2018

Research and Markets has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. [More]
Research report: Orphan Diseases Partnering Terms and Agreements

Research report: Orphan Diseases Partnering Terms and Agreements

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies. [More]
Scientists pave way for improved tools to diagnose, predict and monitor cancer

Scientists pave way for improved tools to diagnose, predict and monitor cancer

Scientists have shown how to better identify and measure vital molecules that control cell behaviour - paving the way for improved tools for diagnosis, prediction and monitoring of cancer. [More]
Scientists pave way for improved tools to predict and monitor cancer

Scientists pave way for improved tools to predict and monitor cancer

Scientists have shown how to better identify and measure vital molecules that control cell behaviour - paving the way for improved tools for diagnosis, prediction and monitoring of cancer. [More]
Researchers report that predominant CA-MRSA strain migrated from sub-Saharan Africa

Researchers report that predominant CA-MRSA strain migrated from sub-Saharan Africa

The predominant strain of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infecting people in Europe, the Middle East and northern Africa derived from a single sub-Saharan ancestor, a team of international researchers reported this week in mBio-, the online open-access journal of the American Society for Microbiology. [More]
NEOMED gets $12 million to support academic researchers on drug development

NEOMED gets $12 million to support academic researchers on drug development

NEOMED, a not-for-profit organization whose mission is to create a bridge between academic research and the pharmaceutical industry, will receive $12 million in funding from the Government of Canada to help academic researchers turn their early discoveries into future medicines. [More]
FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]
Feds to withhold some doctor payment data after inconsistencies

Feds to withhold some doctor payment data after inconsistencies

The Centers For Medicare & Medicaid Services said Friday that, because of data inconsistencies, a third of the records in a database showing drug and device-maker contributions to doctors will be withheld next month when the website goes live. [More]
First Edition: August 18, 2014

First Edition: August 18, 2014

Today's headlines stories about the pervasive nature of Medicare fraud and the difficulties involved in fighting it. [More]
Medical advisory panel recommends new pneumonia vaccine for seniors

Medical advisory panel recommends new pneumonia vaccine for seniors

The experts expressed concern, however, that Medicare rules may hamper some people from getting the new vaccine if they have already had an older version. Also in drug issues, some patient advocates report that insurers are balking at paying for a costly drug to treat hepatitis C if the patients are in drug treatment programs. [More]
23andMe, Pfizer partner to explore genetic factors associated with IBD

23andMe, Pfizer partner to explore genetic factors associated with IBD

23andMe, the leading personal genetics company today announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. [More]
Research shows new drug candidate can stop tumor growth in animal models

Research shows new drug candidate can stop tumor growth in animal models

It's a trick any cat burglar knows: to open a locked door, slide a credit card past the latch. Scientists at The Scripps Research Institute (TSRI) tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be "undruggable." [More]
Complete analysis of the growing manufacturing market of HPAPIs and cytotoxic drugs

Complete analysis of the growing manufacturing market of HPAPIs and cytotoxic drugs

Reportbuyer.com has added a new market research report: HPAPIs and Cytotoxic Drugs Manufacturing Market, 2014 - 2024 [More]
New market research report provides data on Spinal Cord Injury clinical trial scenario

New market research report provides data on Spinal Cord Injury clinical trial scenario

Reportlinker.com announces that a new market research report is available in its catalogue: Spinal Cord Injury Global Clinical Trials Review, H2, 2014. [More]
Global therapeutic market for BBB technologies expected to grow at 64.9% CAGR over 2014-2019

Global therapeutic market for BBB technologies expected to grow at 64.9% CAGR over 2014-2019

Reportlinker.com announces that a new market research report is available in its catalogue: Blood-Brain Barrier Technologies and Global Markets. [More]
Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share. [More]
Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014. [More]
Little-known supportive cells in brain may play major role in cognitive function

Little-known supportive cells in brain may play major role in cognitive function

When you're expecting something-like the meal you've ordered at a restaurant-or when something captures your interest, unique electrical rhythms sweep through your brain. [More]